A meta-analysis of 11 randomized, controlled trials suggests that adherence is better with once-daily than with twice-daily regimens.
Proper adherence to antiretroviral therapy (ART) is essential for achieving virologic suppression and decreasing the risk of disease progression and death. Understanding the factors that influence adherence is of critical importance to designing the most effective regimens. One possible factor is dosing schedule. Until now, studies evaluating the effect of dosing on adherence have been underpowered and therefore inconclusive.
To compare adherence between once-daily and twice-daily antiretroviral dosing, investigators conducted a meta-analysis of 11 trials involving 3029 patients. In each trial, patients were randomized to one of two regimens, and adherence was measured (by pill counts or the Medication Event Monitoring System) for only one o…
Reviewing Authors
Paulina Rebolledo, MD, MSc
Paulina Rebolledo, MD, MSc
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)